Why the Pro Medicus (ASX:PME) share price is getting thumped today

The Pro Medicus Limited (ASX:PME) share price is sinking on Wednesday after its half year result fell short of expectations…

| More on:
asx share price fall represented by investor with head in hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price has come under pressure this morning following the release of its half year results.

In early trade, the health imaging company's shares were down as much as 17% to $38.00.

The Pro Medicus share price has since recovered slightly but remains 8% lower at $41.83 at the time of writing.

Why is the Pro Medicus share price crashing lower?

Investors have been selling Pro Medicus shares on Wednesday after its half year results fell short of the market's lofty expectations.

For the six months ended 31 December, the company reported a 7.8% increase in revenue to $31.6 million. Management advised that the stronger Australian dollar impacted its result. On a constant currency basis, its revenue would have been up 12.4% to $32.9 million.

Currency headwinds also weighed on its profits. Reported underlying profit before tax came in 25.9% higher at $18.76 million but would have been up 29% to $19.7 million in constant currency.

On the bottom line, Pro Medicus delivered a 12.4% increase in net profit after tax to $13.5 million. This includes tax expense of $4.66 million, which represents a tax rate of 25.6%. This compares to a tax rate of 18.6% in 2019.

At the end of the period, the company had cash reserves of $50.9 million and no debt.

This strong balance sheet allowed the Pro Medicus board to declare a fully franked interim dividend of 7 cents per share.

How does this compare to expectations?

According to a note out of Goldman Sachs, Pro Medicus missed on both revenue and earnings.

The broker notes that Pro Medicus feel short of its revenue forecast by 9% and its EBIT forecast by 7%.

This goes some way to explaining the weakness in the Pro Medicus share price today.

What were the drivers of its growth?

Pro Medicus' CEO, Dr Sam Hupert, revealed that the company performed well across all markets despite the restrictions of COVID-19.

He said: "It was a good six months across all jurisdictions. Examination numbers in the first three months of the quarter were still recovering from their April 2020 lows however we were able to make up for the decrease with new clients coming on stream and exam numbers tracking back to pre COVID levels."

The star of the show for the company was arguably the Australian business, which delivered a 22.8% increase in revenue. This was largely due to the rollout of the Healius Ltd (ASX: HLS) contract and the extension of a contract with I-MED.

The company's European operations also had a positive half. This is expected to continue in the second half thanks to its new contract with Ludwig-Maximilians University.

Outlook

No guidance or commentary was given in regard to its second half outlook. This may have disappointed investors and be contributing to the Pro Medicus share price decline today. Though, it is worth noting that this is customary for Pro Medicus.

Positively, Dr Hupert did speak briefly about the company's sales pipeline.

He said: "We have had a very good run of contract wins over the past seven to eight months and pleasingly we have seen an increasing number of opportunities enter the pipeline in addition to those opportunities that have been progressing through the sales cycle. Importantly, the opportunities are across a range of market segments, including some for multiple Visage products, as well as a healthy mix of Cloud and non-Cloud."

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »

A woman puts her hands up as she smashes and breaks through a glass ceiling.
Share Gainers

How these 5 ASX 200 stocks are smashing the benchmark this week

These fives ASX 200 stocks have made some very happy shareholders this week. Here’s how.

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Catalyst Metals, Duratec, Nufarm, and Rio Tinto shares are dropping today

These shares are ending the week in the red. But why?

Read more »

A smiling woman at a hardware shop selects paint colours from a wall display.
Broker Notes

After its strategy day, what does Macquarie think Wesfarmers shares are worth?

Let's see what the broker is saying about this blue chip.

Read more »